Details of the Drug Combination

General Information of Drug Combination (ID: DCNP4A6)

Drug Combination Name

PMID28870136-Compound-43 Altretamine

Indication

Disease Entry	Status	REF
Adenocarcinoma	Investigative	[1]

Component Drugs

PMID28870136-Compound-43 DMWGV8N

Altretamine DMKLAYG

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: HCT116

Zero Interaction Potency (ZIP) Score: 4.4

Bliss Independence Score: 5.39

Loewe Additivity Score: 2.69

LHighest Single Agent (HSA) Score: 0.01

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

PMID28870136-Compound-43 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Ecto-5'-nucleotidase (CD73)	TTK0O6Y	5NTD_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

Indication(s) of Altretamine

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Approved	[2]

Altretamine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Breaker	[4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Childhood T acute lymphoblastic leukemia	DC7LI19	CCRF-CEM	Investigative	[5]
Clear cell renal cell carcinoma	DC2B90M	TK-10	Investigative	[5]
Glioblastoma	DCI9JSL	SNB-75	Investigative	[5]
Invasive ductal carcinoma	DCIGVWE	HS 578T	Investigative	[6]
Cutaneous melanoma	DCMW95C	SK-MEL-5	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCLVLNS	OVCAR-8	Investigative	[1]
High grade ovarian serous adenocarcinoma	DC7GC3E	OVCAR-4	Investigative	[1]
Ovarian serous cystadenocarcinoma	DCOOMVF	SK-OV-3	Investigative	[1]
Pleural epithelioid mesothelioma	DC4J0U5	NCI-H226	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 DrugCom(s)

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
3	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
4	Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
5	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.